Application of molecular technologies for phosphoproteomic analysis of clinical samples

• Published in: Oncogene Vol. 34; no. 7; pp. 805 - 814
• Main Authors: Pierobon, M, Wulfkuhle, J, Liotta, L, Petricoin, E
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 12.02.2015; Nature Publishing Group
• Subjects: 631/1647/2067; 631/67/1059/153; Apoptosis; Biomarkers - metabolism; Cancer; Care and treatment; Cell Biology; Deactivation; Drug Delivery Systems; Human Genetics; Humans; Inhibitor drugs; Internal Medicine; Mass spectroscopy; Medicine; Medicine & Public Health; Methods; Monoclonal antibodies; Nanotechnology; Oncology; Oncology, Experimental; Phosphoproteins - genetics; Phosphoproteins - metabolism; Phosphorylation; Phosphorylation - genetics; Post-translation; Protein arrays; Protein Processing, Post-Translational; Proteome - genetics; Proteome - metabolism; Proteomes; Proteomics; Proteomics - instrumentation; Proteomics - methods; review; Therapeutic targets
• ISSN: 0950-9232; 1476-5594
• DOI: 10.1038/onc.2014.16

The integration of small kinase inhibitors and monoclonal antibodies into oncological practice has opened a new paradigm for treating cancer patients. As proteins are the direct targets of the new generations of targeted therapeutics, many of which are kinase/enzymatic inhibitors, there is an increasing interest in developing technologies capable of monitoring post-translational changes of the human proteome for the identification of new predictive, prognostic and therapeutic biomarkers. It is well known that the vast majority of the activation/deactivation of these drug targets is driven by phosphorylation. This review provides a description of the main proteomic platforms (planar and bead array, reverse phase protein microarray, phosphoflow, AQUA and mass spectrometry) that have successfully been used for measuring changes in phosphorylation level of drug targets and downstream substrates using clinical specimens. Major emphasis was given to the strengths and weaknesses of the different platforms and to the major barriers that are associated with the analysis of the phosphoproteome. Finally, a number of examples of application of the above-mentioned technologies in the clinical setting are reported.